Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery. The AIM-traded firm said the research suggested potential applications of POLB 001 in rare and orphan blood cancers, aligning with its commitment to addressing severe medical conditions.

In addition to the promising outlook for POLB 001, Poolbeg said it intended to advance its development alongside its existing portfolio, including programmes targeting influenza, AI-driven drug discovery, and oral delivery of GLP-1 for metabolic disorders.

With the field of cancer immunotherapies projected to reach $100bn to $140bn by 2030, the demand for effective CRS management was described as imminent.

CRS-related hospitalisation costs amount to an estimated $5.5bn, which Poolbeg said underscored the urgent need for preventative interventions.

Notably, Poolbeg's recent in vivo results for POLB 001 showed promising outcomes in ameliorating CRS symptoms, accompanied by dose-dependent reductions in proinflammatory cytokines.

The development of an oral preventative therapy held potential not only to alleviate healthcare system burdens, but also to enhance patient access to life-saving treatments, possibly extending beyond specialist centres.

"Rare and orphan disease medicines fit Poolbeg's efficient capital model particularly well," said chief executive officer Jeremy Skillington.

"Clinical development is typically more cost efficient and the market opportunity remains high because of the high unmet medical need.

"There is also a very active merger and acquisition market in this sector which Amryt took advantage of."

Skillington said the company saw the strategic approach as "highly complementary" to its existing programmes.

"The former Amryt team that have joined Poolbeg have an exceptional track record, have hit the ground running and are aligned with our vision of rapidly generating revenues and creating value for shareholders."

At 1412 GMT, shares in Poolbeg Pharma were down 0.74% at 9.28p.

Reporting by Josh White for

Share this article

Related Sharecast Articles

Billionaire Issa nearing deal to sell Asda stake to TDR Capital - report
(Sharecast News) - US private equity firm TDR Capital is reportedly closing in on a deal to buy petrol station billionaire Zuber Issa's stake in supermarket chain Asda.
Billionaire Issa nearing deal to sell Asda stake to TDR Capital
(Sharecast News) - Private equity firm TDR Capital is reportedly closing in on a deal to buy petrol station billionaire Zuber Issa's stake in supermarket chain Asda.
DS Smith tumbles as Mondi abandons pursuit
(Sharecast News) - DS Smith tanked on Friday after Mondi said it would not be making an offer for the rival packaging group, clearing the path for a takeover by International Paper.
Eqtec agrees amendment to Verde subscription
(Sharecast News) - Waste-to-energy technology developer Eqtec updated the market on the Verde Corporation subscription on Friday, confirming that an amendment to the subscription letter had been agreed upon with Verde.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.